A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT ID: NCT06476808
Last Updated: 2025-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
240 participants
INTERVENTIONAL
2024-09-06
2028-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
NCT01986218
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
NCT00329004
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
NCT07160725
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
NCT00569036
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
NCT01292655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Dose Escalation
BMS-986463
Specified dose on specified days
Arm 2: Dose Expansion
BMS-986463
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986463
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
* Participants must have an unresectable/metastatic carcinoma.
Exclusion Criteria
* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
* Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Local Institution - 0045
Columbus, Ohio, United States
Local Institution - 0046
Dallas, Texas, United States
BC Cancer Vancouver
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Local Institution - 0031
Villejuif, Val-de-Marne, France
Local Institution - 0036
Borddeaux Cedex, , France
Local Institution - 0035
Lyon, , France
Local Institution - 0032
Rozzano, Milano, Italy
Local Institution - 0033
Milan, , Italy
Local Institution - 0041
Avda.Pio XII 36,, , Spain
Local Institution - 0042
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
First line of the email MUST contain the NCT# and Site#
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anastasia Martynova, Site 0003
Role: primary
David Berz, Site 0006
Role: primary
Martin Gutierrez, Site 0001
Role: primary
Site 0045
Role: primary
Site 0046
Role: primary
Yvette Drew, Site 0026
Role: primary
Amit Oza, Site 0027
Role: primary
Diane Provencher, Site 0028
Role: primary
Susie Lau, Site 0024
Role: primary
Site 0031
Role: primary
Site 0036
Role: primary
Site 0035
Role: primary
Site 0032
Role: primary
Site 0033
Role: primary
Site 0041
Role: primary
Site 0042
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA231-0000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.